Global Blood Therapeutics Inc (NASDAQ:GBT) insider Peter Radovich sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $50.00, for a total value of $750,000.00. Following the completion of the transaction, the insider now owns 17,684 shares of the company’s stock, valued at $884,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Peter Radovich also recently made the following trade(s):

  • On Monday, October 30th, Peter Radovich sold 12,500 shares of Global Blood Therapeutics stock. The shares were sold at an average price of $35.00, for a total value of $437,500.00.

Global Blood Therapeutics Inc (GBT) opened at $56.60 on Friday. Global Blood Therapeutics Inc has a one year low of $14.70 and a one year high of $57.75.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.04). During the same quarter last year, the company posted ($0.58) earnings per share. research analysts anticipate that Global Blood Therapeutics Inc will post -2.53 EPS for the current year.

A number of research analysts have weighed in on GBT shares. Zacks Investment Research upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Cowen reiterated a “buy” rating and set a $83.00 target price on shares of Global Blood Therapeutics in a research note on Thursday, November 9th. Wedbush reiterated an “outperform” rating and set a $73.00 target price on shares of Global Blood Therapeutics in a research note on Friday, December 15th. Nomura lifted their target price on Global Blood Therapeutics to $91.00 and gave the stock a “buy” rating in a research note on Monday, December 11th. Finally, Oppenheimer set a $79.00 target price on Global Blood Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $62.07.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA boosted its stake in Global Blood Therapeutics by 694.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after purchasing an additional 3,975 shares during the period. Jane Street Group LLC bought a new stake in Global Blood Therapeutics in the 3rd quarter valued at $200,000. Trexquant Investment LP bought a new stake in Global Blood Therapeutics in the 3rd quarter valued at $202,000. Dynamic Technology Lab Private Ltd bought a new stake in Global Blood Therapeutics in the 3rd quarter valued at $205,000. Finally, Raymond James Financial Services Advisors Inc. bought a new stake in Global Blood Therapeutics in the 3rd quarter valued at $230,000. Institutional investors and hedge funds own 85.72% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Global Blood Therapeutics Inc (GBT) Insider Sells 15,000 Shares of Stock” was first posted by Watch List News and is owned by of Watch List News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.watchlistnews.com/insider-selling-global-blood-therapeutics-inc-gbt-insider-sells-15000-shares-of-stock/1806749.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.